Picture of RxSight logo

RXST — RxSight News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Rxsight Inc expected to post a loss of 27 cents a share - Earnings Preview

* Rxsight Inc  RXST.OQ   RXST.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 6 for the
period ending March 31 2024
    * The Aliso Viejo California-based  company is expected to
report
a 57.6% increase in revenue to $27.559 million from $17.49
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Rxsight Inc is for a
loss
of 27 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rxsight Inc
is
$63.00​, above​ its last closing price of $61.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.36       -0.36      -0.26     Beat    28.2
 Sep. 30 2023  -0.43       -0.43      -0.31     Beat    28.5
 Jun. 30 2023  -0.47       -0.47      -0.39     Beat    17​
 Mar. 31 2023  -0.53       -0.53      -0.42     Beat    20.8
 ​​Dec.        -0.77       -0.75      -0.56     Beat    25.1
 31 2022                                                
 Sep. 30 2022  -0.71       -0.71      -0.61     Beat    14.5​
 Jun. 30 2022  -0.69       -0.69      -0.61     Beat    12.2
 Mar. 31 2022  -0.65       -0.65      -0.64     Beat    1
 This summary was machine generated May 4 at 02:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on RxSight

See all news